KR20230144529A - 키나아제 억제제 및 이의 용도 - Google Patents

키나아제 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20230144529A
KR20230144529A KR1020237024086A KR20237024086A KR20230144529A KR 20230144529 A KR20230144529 A KR 20230144529A KR 1020237024086 A KR1020237024086 A KR 1020237024086A KR 20237024086 A KR20237024086 A KR 20237024086A KR 20230144529 A KR20230144529 A KR 20230144529A
Authority
KR
South Korea
Prior art keywords
optionally substituted
pharmaceutically acceptable
compound
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237024086A
Other languages
English (en)
Korean (ko)
Inventor
첸 첸
Original Assignee
에이비엠 쎄라퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비엠 쎄라퓨틱스 코포레이션 filed Critical 에이비엠 쎄라퓨틱스 코포레이션
Publication of KR20230144529A publication Critical patent/KR20230144529A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237024086A 2020-12-16 2021-12-16 키나아제 억제제 및 이의 용도 Pending KR20230144529A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126364P 2020-12-16 2020-12-16
US63/126,364 2020-12-16
PCT/US2021/063724 WO2022133040A1 (en) 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20230144529A true KR20230144529A (ko) 2023-10-16

Family

ID=79425572

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024086A Pending KR20230144529A (ko) 2020-12-16 2021-12-16 키나아제 억제제 및 이의 용도

Country Status (9)

Country Link
US (1) US20240083844A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263501A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023554391A (cg-RX-API-DMAC10.html)
KR (1) KR20230144529A (cg-RX-API-DMAC10.html)
CN (1) CN117083265A (cg-RX-API-DMAC10.html)
AU (1) AU2021401282A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179325A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023006434A (cg-RX-API-DMAC10.html)
WO (1) WO2022133040A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116356017A (zh) * 2022-12-12 2023-06-30 南京腾辰生物科技有限公司 一种甲状腺肿瘤良恶性早期诊断标志物及其应用
WO2025184877A1 (zh) * 2024-03-07 2025-09-12 中国医学科学院基础医学研究所 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用
WO2026064501A1 (en) * 2024-09-18 2026-03-26 The University Of Chicago Reversible and irreversible kinome probes and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444866T3 (es) * 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
GB0812913D0 (en) * 2008-07-15 2008-08-20 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2814617C (en) * 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
WO2012055953A1 (en) * 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
JP2015517574A (ja) * 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
WO2019006548A1 (en) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF

Also Published As

Publication number Publication date
JP2023554391A (ja) 2023-12-27
EP4263501A1 (en) 2023-10-25
WO2022133040A1 (en) 2022-06-23
MX2023006434A (es) 2023-06-13
CA3179325A1 (en) 2022-06-23
US20240083844A1 (en) 2024-03-14
CN117083265A (zh) 2023-11-17
AU2021401282A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
CN115836070B (zh) 作为egfr抑制剂的稠环化合物及其制备方法和应用
CN112778284B (zh) 一种嘧啶并环衍生物及其在医药上的应用
RU2687060C2 (ru) Фармацевтические соединения
EP3191472B1 (en) Compounds and compositions as raf kinase inhibitors
EP3684772B1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
KR102682216B1 (ko) 칸나비노이드 수용체 조절제
WO2025002430A1 (zh) 一种5元杂芳基衍生物及其在医药上的应用
KR20220119088A (ko) Kras 돌연변이체 단백질 억제제
KR20190086442A (ko) 피리딘 화합물
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
US20240083844A1 (en) Kinase inhibitors and uses thereof
WO2019189555A1 (ja) 複素環化合物
WO2024193464A1 (zh) 一种含氮三并环衍生物及其在医药上的应用
CN110028507A (zh) 具有trk激酶抑制活性化合物、制备方法、组合物及用途
CN110156783B (zh) 作为pi3k/mtor抑制剂的嘧啶基取代的稠合喹啉化合物
CN118255780A (zh) 一种抑制并降解c-MYC的化合物及其医药上的应用
KR102668390B1 (ko) 신규한 pan-RAF 키나아제 저해제 및 이의 용도
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
CN113166109B (zh) 氨基吡啶类化合物及其制备方法和用途
WO2025103489A1 (zh) 一种hpk1降解剂及其在医药上的应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
HK40103623A (en) Kinase inhibitors and uses thereof
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902